Ezetimibe/atorvastatin
| Combination of | |
|---|---|
| Ezetimibe | Hypolipidemic agent |
| Atorvastatin | Statin |
| Clinical data | |
| Trade names | Liptruzet, Atozet |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| PubChem CID | |
| KEGG | |
Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug. In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet.[1] It has also been approved to reduce elevated total cholesterol and elevated LDL in patients diagnosed with homozygous familial hypercholesterolemia as an adjunctive treatment to other hyperlipidemia treatments.[2]
Some cardiologists opposed the approval, because the combination reduced LDL cholesterol in a clinical trial, but it did not reduce heart disease. A clinical trial studying the endpoints of heart attacks, strokes and heart-related deaths is scheduled to conclude in 2014.[3]
Liptruzet was withdrawn from sale by its manufacturer in June 2015, but not for reasons of safety or effectiveness.[4]
- ^ "FDA Approves Merck's LIPTRUZET (ezetimibe and atorvastatin), a New Product That Can Help Powerfully Lower LDL Cholesterol". Business Wire. May 6, 2013. Retrieved May 6, 2013.
- ^ "Liptruzet." CenterWatch. Web. 28 Oct. 2014.
- ^ Drug to Cut Cholesterol Is Approved by the F.D.A. By Katie Thomas, New York Times, May 3, 2013
- ^ Determination That LIPTRUZET (Ezetimibe and Atorvastatin) Tablets, 10 Milligrams/10 Milligrams, 10 Milligrams/20 Milligrams, 10 Milligrams/40 Milligrams, and 10 Milligrams/80 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness Federal Register: Notice by the Food and Drug Administration on 11/20/2015.